| Identification | Back Directory | [Name]
FF-10502 | [CAS]
184302-49-6 | [Synonyms]
FF-10502
FF-10502-01
4-Amino-1-(2-deoxy-2-fluoro-4-thio-β-Darabinofuranosyl)-2(1H)-pyrimidinone
2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)- | [Molecular Formula]
C9H12FN3O3S | [MOL File]
184302-49-6.mol | [Molecular Weight]
261.27 |
| Hazard Information | Back Directory | [Uses]
FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1]. | [in vivo]
FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1]. | Animal Model: | Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1]. | | Dosage: | 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg | | Administration: | Tail vein injection; once weekly; for 4 weeks | | Result: | Suppressed tumor growth in a dose-dependent manner in mice.
|
| [References]
[1] Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. DOI:10.1124/jpet.118.248740 |
|
| Company Name: |
NewCan Biotech Limited
|
| Tel: |
+86-0571-86912261 +86-15658003402 |
| Website: |
https://www.newcanbio.com/ |
|